ClinicalTrials.gg
CompletedNCT00554970P202Updated Jan 9, 2014Results posted

A Study of 2 Doses of MAP0010 in Adult Asthmatics

A Phase 2 interventional study of MAP0010 low dose and MAP0010 high dose in Asthma, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2014-01-09.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
85th of 108
32 · median 124
Started
2007
with 11 others
Phase 2
5 of 110
none open now
Registered
32nd of 110
by date
Lead sponsor
5 of 110
Allergan

Among the 110 studies testing budesonide in Asthma, this one is the 85th largest by enrollment of the 108 interventional ones that give a count, is one of 12 that started in 2007, is one of 5 in phase 2, and was the 32nd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Adult Asthmatics
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adult asthmatics with mild to moderate persistent asthma.
  • 18 to 45 (up to the 46th birthday) years of age.
  • Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH/NHLBI, EPR-3 criteria.
  • Able to withhold short-acting bronchodilators (e.g., albuterol or ipratropium bromide) for at least 4 hours prior to clinic visits.
  • Baseline greater than or equal to 50% of predicted normal.

Exclusion criteria

Exclusion Criteria:

  • Any other significant illness/abnormality
  • A history of upper or lower respiratory tract infection within 2 weeks
  • A history of acute or severe asthma attack requiring ICU admission or ventilatory support.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Other
    Treatment 1 then Treatment 2

    Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.

    Drug: MAP0010 low dose · Drug: Budesonide inhalation suspension 0.25mg

  • Other
    Treatment 2 then Treatment 1

    Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.

    Drug: MAP0010 low dose · Drug: Budesonide inhalation suspension 0.25mg

  • Other
    Treatment 3 then Treatment 4

    Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.

    Drug: MAP0010 high dose · Drug: Budesonide inhalation suspension 0.5mg

  • Other
    Treatment 4 then Treatment 3

    Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.

    Drug: MAP0010 high dose · Drug: Budesonide inhalation suspension 0.5mg

Interventions

  • a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol

  • a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol

  • a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol

    Also known as: Pulmicort Respules®

  • a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol

    Also known as: Pulmicort Respules®

06

What researchers measure

Primary outcomes

  1. Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

    The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).

    Time frame: Day 1 hour 12

  2. Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

    The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).

    Time frame: Day 8 hour 12

  3. AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

    The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).

    Time frame: Day 1 hour 12

  4. AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

    The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).

    Time frame: Day 8 hour 12

  5. Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

    Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.

    Time frame: Day 1 hour 12

  6. Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

    Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.

    Time frame: Day 8 hour 12

07

Results

Posted Oct 23, 2013

Participant flow

Period 1
Participant flow — Period 1
MilestoneTreatment 1 Then Treatment 2Treatment 2 Then Treatment 1Treatment 3 Then Treatment 4Treatment 4 Then Treatment 3
Started8888
Completed7888
Not completed1000
Period 2
Participant flow — Period 2
MilestoneTreatment 1 Then Treatment 2Treatment 2 Then Treatment 1Treatment 3 Then Treatment 4Treatment 4 Then Treatment 3
Started7888
Completed7878
Not completed0010

Outcome measures

PrimaryCmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).

Time frame:
Day 1 hour 12
Reported as:
Mean · pg/ml
Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
pg/mlMAP0010 High DosePulmicort Respules® 0.50 mgMAP0010 Low DosePulmicort Respules® 0.25 mg
Cmax of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg250 ± 161365 ± 203168 ± 130197 ± 102
PrimaryCmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).

Time frame:
Day 8 hour 12
Reported as:
Mean · pg/ml
Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
pg/mlMAP0010 High DosePulmicort Respules® 0.50 mgMAP0010 Low DosePulmicort Respules® 0.25 mg
Cmax of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg528 ± 257530 ± 334366 ± 262315 ± 206
PrimaryAUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).

Time frame:
Day 1 hour 12
Reported as:
Mean · pg*min/ml
AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
pg*min/mlMAP0010 High DosePulmicort Respules® 0.50 mgMAP0010 Low DosePulmicort Respules® 0.25 mg
AUC(0-inf) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg19400 ± 728055900 ± 1980010300 ± 462026900 ± 7420
PrimaryAUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

The AUC(0-inf) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).

Time frame:
Day 8 hour 12
Reported as:
Mean · pg*min/ml
AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
pg*min/mlMAP0010 High DosePulmicort Respules® 0.50 mgMAP0010 Low DosePulmicort Respules® 0.25 mg
AUC(0-inf) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg58700 ± 2570090100 ± 3820035500 ± 1500045200 ± 19500
PrimaryHalf-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.

Time frame:
Day 1 hour 12
Reported as:
Mean · min
Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
minMAP0010 High DosePulmicort Respules® 0.50 mgMAP0010 Low DosePulmicort Respules® 0.25 mg
Half-life (t1/2) of Budesonide on Day 1 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg168 ± 95.7207 ± 110112 ± 49.0179 ± 75.8
PrimaryHalf-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg

Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.

Time frame:
Day 8 hour 12
Reported as:
Mean · min
Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg
minMAP0010 High DosePulmicort Respules® 0.50 mgMAP0010 Low DosePulmicort Respules® 0.25 mg
Half-life (t1/2) of Budesonide on Day 8 After Administration of MAP0010 Low Dose, MAP0010 High Dose, Pulmicort Respules® 0.25mg, and Pulmicort Respules® 0.5mg193 ± 67.2192 ± 66.3248 ± 192230 ± 130

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment 1 Then Treatment 2—0/8 (0%)7/8 (87.5%)
Treatment 2, Then Treatment 1—0/8 (0%)2/8 (25%)
Treatment 3 Then Treatment 4—0/8 (0%)3/8 (37.5%)
Treatment 4 Then Treatment 3—0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTreatment 1 Then Treatment 2Treatment 2, Then Treatment 1Treatment 3 Then Treatment 4Treatment 4 Then Treatment 3
Iron deficiency anaemiaBlood and lymphatic system disorders1/80/80/80/8
NauseaGastrointestinal disorders1/80/80/80/8
VomitingGastrointestinal disorders1/80/81/80/8
MalaiseGeneral disorders1/80/80/80/8
Skin infectionInfections and infestations0/81/80/80/8
NasopharyngitisInfections and infestations0/81/80/80/8
Viral infectionInfections and infestations0/80/81/80/8
HeadacheNervous system disorders1/80/80/81/8
SyncopeNervous system disorders0/80/80/81/8
Nasal congestionRespiratory, thoracic and mediastinal disorders0/80/81/81/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment 1 Then Treatment 2Treatment 2, Then Treatment 1Treatment 3 Then Treatment 4Treatment 4 Then Treatment 3Total
Mean27.4 ± 8.930.4 ± 7.230.0 ± 8.329.1 ± 6.929.2 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Treatment 1 Then Treatment 2Treatment 2, Then Treatment 1Treatment 3 Then Treatment 4Treatment 4 Then Treatment 3Total
Female363719
Male525113
08

Study locations

1 site
  • West Coast Clinical Trials Phase 2-4, LLC
    Long Beach, California 90806, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jan 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2007
First posted
Nov 7, 2007
Start
Nov 2007
Primary completionActual
Jan 2008
CompletionActual
Mar 2008
Results first posted
Oct 23, 2013
Last update
Jan 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00554970
Lead sponsor
Allergan
Collaborators
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Responsible party
Sponsor
First posted
Nov 7, 2007
Start date
Nov 2007
Primary completion
Jan 2008
Completion
Mar 2008
Results posted
Oct 23, 2013
Last update
Jan 9, 2014

Study contacts

Medical Director
study director · MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion